Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6-17 years

Expert Opinion on Biological Therapy

Volumn 13, Issue 10, 2013, Pages 1451-1465

  Mitchell, Ruth ^a   Trück, Johannes ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

13 valent pneumococcal conjugate vaccine; Adolescents; Children; PCV 13; Pneumococcal disease; Pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY BLOOD LEVEL; ARTICLE; ASPLENIA; CHILD CARE; CHILDHOOD CANCER; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; GROUPS BY AGE; HERD IMMUNITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; MORBIDITY; PNEUMOCOCCAL INFECTION; PNEUMONIA; RISK FACTOR; SEROTYPE; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; CHILD; HUMANS; IMMUNIZATION SCHEDULE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84884220307     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.824419     Document Type: Article

References (94)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 2009;374(9693):893-902
2. Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007;25(13):2398-405
3. FDA. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar
4. US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD; 2011. Available from: Http://www.fda. gov/downloads/ advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/ vaccinesandrelatedbiological productsadvisorycommittee/ucm279680. pdf [Cited 24 March 2013
5. European Medicines Agency: Assessment Report Prevenar 13. 2012. Available from: Http://www.ema.europa.eu/docs/ en-GB/document;library/EPAR;- Assessment;Report;-Variation/human/ 001104/WC500139411.pdf [Cited 19 March 2013
6. Department of Health and Human Services. Statistical Review And Evaluation BLA 125324/767. 2012. Available from: Http://www.fda.gov/ downloads/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ UCM337688.pdf [Cited 19 March 2013
7. Laferriere C. The immunogenicity of pneumococcal polysaccharides in infants and children: A meta-regression. Vaccine 2011;29(40):6838-47
8. Licciardi PV, Balloch A, Russell FM, et al. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012;129(3):794-800; e2
9. Lesinski GB, Westerink MAJ. Novel vaccine strategies to T-independent antigens. J Microbiol Methods 2001;47(2):135-49
10. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348(18):1737-46
11. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19(3):187-95
12. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: Updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9):779-81
13. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344(6):403-9
14. Tocheva AS, Jefferies JMC, Rubery H, et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011;29(26):4400-4
15. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet Infect Dis 2011;11(10):760-8
16. Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005;192(11):1988-95
17. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project. PLoS Med 2010;7(10):e1000348
18. Kaye P, Malkani R, Martin S, et al. Invasive Pneumococcal Disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines: Health Protection Agency. 27th annual meeting of the European Society For Paediatric Infectious Diseases (ESPID); Brussels, Belgium; 2009
19. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2010;59(11 RR):1-19
20. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25(19):3816-26
21. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: A double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010;29(12):e80-90
22. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vacc Immunol 2010;17(6):1017-26
23. Bryant KA, Block SL, Baker SA, et al. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine. Pediatrics 2010;125(5):866-75
24. WHO/Health Canada Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. 2008. Available from: Http://www.who.int/biologicals/ publications/meetings/areas/vaccines/ pneumococcal/Pneumo Meeting Report FINAL IK 24-Dec-08.pdf [Cited 20 March 2013
25. Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010-11. 8th International Symposium on Pneumococci and Pneumococcal Diseases; Brazil; 2012
26. Link-Gelles R, Taylor T, Moore MR. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013;31(22):2572-7
27. Health Protection Agency. Current Epidemiology of Invasive Pneumococcal Disease (IPD): In Prevenar 13- Not In Prevenar PCV7. 2013. Available from: Http://www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/ Pneumococcal/EpidemiologicalData Pneumococcal/CurrentEpidemiology Pneumococcal/InPrevenar13NotIn PrevenarPCV7 / [Cited 20 March 2013
28. Joint Committee on Vaccination and Immunisation: Pneumococcal sub-committee. 2012. Available from: Https://http://www.wp.dh.gov.uk/ transparency/files/2012/07/JCVI-minutes- Pneumococcal-sub-committee-meetingheld- on-30-May-2012.pdf [Cited 07 February 2013
29. Trück J, Lazarus R, Clutterbuck EA, et al. The zwitterionic type I Streptococcus pneumoniae polysaccharide does not induce memory B cell formation in humans. Immunobiology 2013;218(3):368-72
30. Poolman J, Kriz P, Feron C, et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009;27(24):3213-22
31. Kim JO, Romero-Steiner S, Sørensen UBS, et al. Relationship between Cell Surface Carbohydrates and Intrastrain Variation on Opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999;67(5):2327-33
32. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043-51
33. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. J Am Med Assoc 2006;295(14):1668-74
34. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR 2005;54(36):893-7
35. European Centre for Disease Prevention and Control. Vaccination Schedules. 2013. Available from: Http://ecdc.europa. eu/en/activities/ surveillance/euvac/ schedules/Pages/schedules.aspx [Cited 27 March 2013
36. Bennett NM, Whitney CG, Moore M, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61(40):816-19
37. Department of Health. Green Book: Immunisation against infectious disease. Department of Health; London, UK: 2012
38. Health Protection Agency: Invasive pneumococcal disease incidence rate per 100,000 population by age grouping England and Wales, 1996-2005. 2008. Available from: Http://www.hpa. org.uk/Topics/InfectiousDiseases/Infections AZ/Pneumococcal/Epidemiological DataPneumococcal/Background EpidemiologyPneumococcal/IPDGraphs/ pneumoIPDIncidenceRate/ [Cited 2012
39. CDC. Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae. 2011. Available from: Http://www.cdc.gov/abcs/reports-findings/ survreports/spneu11.html [Cited 21 March 2013
40. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004;363(9424):1871-2
41. Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005;133(5):891-8
42. Cardozo DM, Nascimento-Carvalho CM, Andrade A-LSS, et al. Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents. J Med Microbiol 2008;57(2):185-9
43. Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years. 2011. Available from: Http://clinicaltrials. gov/show/NCT00761631 [Cited 2013 27 March 2013
44. Frenck Jr. R, Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2011;30(12):1086-91
45. Payton T, Girgenti D, Frenck R, et al. Immunogenicity, safety, and tolerability of three lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States. Pediatr Infect Dis J 2013; [Epub ahead of print
46. Frenck Jr. R, Thompson A, Senders S, et al. 13-valent pneumococcal conjugate vaccine in older children and teens either previously immunized with or naíve to 7-valent pneumococcal conjugate vaccine. 8th International Symposium on Pneumococci and Pneumococcal Diseases Iguacu Falls; Brazil; 2012
47. Quinet B, Laudat F, Gurtman A, et al. PCV-elicited antibody persistence and responses to PCV13 in children previously vaccinated with 4 doses of either PCV7 or PCV13. 8th International Symposium on Pneumococci and Pneumococcal Diseases Iguacu Falls; Brazil; 2012
48. Trück J, Tatangeli F, Snape M, et al. Antibody persistence to pre-school years following immunisation at 2, 4 and 12 months with 7-valent and 13-valent pneumococcal glycoconjugate vaccines. 8th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); Melbourne, Australia; 2011
49. Trück J, Snape MD, Tatangeli F, et al. Antibody persistence to pre-school years following immunisation at 2, 4 and 12 months with 7-valent and 13-valent pneumococcal glycoconjugate vaccines. 31st annual meeting of the European Society For Paediatric Infectious Diseases; Milan, Italy; 2013
50. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24 England
51. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008;8(1):67-80
52. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vacc and Immunother 2012;8(2):161-73
53. King Jr. JC, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15(3):192-6
54. Spoulou VI, Tsoumas DL, Papaevangelou VG, et al. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005;23(46-47):5289-93
55. Tarragó D, Casai J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005;12(1):165-70
56. De Montalembert M, Abboud MR, Fiquet A, et al. A 2-dose schedule of 13-valent Pneumococcal Conjugate Vaccine (PCV13) given to children with sickle cell disease previously immunized with 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a phase 3 study. 54th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 2012
57. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25(10):920-9
58. Thanee C, Pancharoen C, Likitnukul S, et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine 2011;29(35):5886-91
59. Antin JH, Guinan EC, Avigan D, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(3):213-22
60. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003;101(3):831-6
61. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007;109(6):2322-6
62. Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: A prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009;28(8):688-92
63. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007;25(13):2451-7
64. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-8
65. French N, Gordon SB, Mwalukomo T, et al. A TRIAL of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362(9):812-22
66. Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2013;56(5):e59-67
67. Remberger M, Ackefors M, Berglund S, et al. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. Biol Blood Marrow Transplant 2011;17(11):1688-97
68. HRSA. OPTN/SRTR Annual Report: One Year Adjusted Patient Survival by Organ and Year of Transplant, 1998 to 2007. 2009. Available from: Http://optn.transplant.hrsa.gov/ar2009/ 112a-dh.htm [Cited 30 March 2013]
69. Rozenbaum MH, Van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: Economic analysis. BMJ (Online) 2012;345:7882
70. Lu CL, Hung CC, Chuang YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vacc Immunother 2013;9(2):398-404
71. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133(2):275-8
72. Smets F, Bourgois A, Vermylen C, et al. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine 2007;25(29):5278-82
73. Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011;52(6):736-42
74. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9):1318-25
75. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: Is hyporesponsiveness an issuëLancet Infect Dis 2007;7(9):597-606
76. Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: What is the evidencëCurr Opin Infect Dis 2012;25(3):292-303
77. Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008(1):CD000422
78. Trück J, Lazarus R, Jonsdottir I, et al. Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: There is no need for a vaccine program in older adults at present. Clin Infect Dis 2012;55(11):1577-9
79. Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30(48):6802-8
80. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19(3):187-95
81. Russell FM, Carapetis JR., Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vacc Immunol 2010;17(12):1970-6
82. Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010;29(4):289-93
83. Hanage WP, Finkelstein JA, Huang SS, et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010;2(2):80-4
84. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
85. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 2006;367(9512):740-8
86. Ogunniyi AD, Grabowicz M, Briles DE, et al. Development of a Vaccine against Invasive Pneumococcal Disease Based on Combinations of Virulence Proteins of Streptococcus pneumoniae. Infect Immun 2007;75(1):350-7
87. Tai SS. Streptococcus pneumoniae protein vaccine candidates: Properties, activities and animal studies. Crit Rev Microbiol 2006;32(3):139-53
88. Read RC, Baxter D, Chadwick DR, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. 31st annual meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy; 2013
89. Vieira S, Baldacci E, Carneiro-Sampaio M, et al. Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease. Pediatr Nephrol 2009;24(1):83-9
90. Mikoluc B, Kayhty H, Bernatowska E, et al. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis 2008;27(10):923-8
91. Forstner C, Plefka S, Tobudic S, et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 2012;30(37):5449-52
92. Cheng FWT, Ip M, Chu YYL, et al. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Arch Dis Child 2012;97(4):358-60
93. Pao M, Papadopoulos EB, Chou J, et al. Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biol Blood Marrow Transplant 2008;14(9):1022-30
94. Glesby MJ, Brinson CC, Greenberg RN, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV+ adults with prior 23-valent pneumococcal polysaccharide vaccination. 20th Conference on Retroviruses and Opportunistic Infections (CROI); Atlanta, GA, USA; 2013